Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects

References

• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al.; American Academy of Dermatology Work, G. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–174.
   PubMed Web of Science ®Google Scholar
• Dayangac-Erden D, Karaduman A, Erdem-Yurter H. Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch Dermatol Res. 2007;299:487–491.
   PubMed Web of Science ®Google Scholar
• Halsall JA, Osborne JE, Pringle JH, et al. Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Pharmacogenet Genomics. 2005;15:349–355.
   PubMed Web of Science ®Google Scholar
• Smith G, Weidlich S, Dawe RS, et al. Glutathione S-transferase M1 (GSTM1) genotype but not GSTT1 or MC1R genotype influences erythemal sensitivity to narrow band (TL-01) UVB phototherapy. Pharmacogenet Genomics. 2011;21:217–224.
   PubMed Web of Science ®Google Scholar
• Ryan C, Renfro L, Collins P, et al. Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis. Br J Dermatol. 2010;163:1056–1063.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith RL, Campalani E, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008;128:1925–1929.
   PubMed Web of Science ®Google Scholar
• Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol. 2007;127:1860–1867.
   PubMed Web of Science ®Google Scholar
• Vasilopoulos Y, Sarri C, Zafiriou E, et al. A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. Pharmacogenomics J. 2014;14:523–525.
   PubMed Web of Science ®Google Scholar
• Gallo E, Cabaleiro T, Roman M, et al. The relationship between tumour necrosis factor (TNF)-alpha promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-alpha therapy in psoriasis: a case-control study. Br J Dermatol. 2013;169:819–829.
   PubMed Web of Science ®Google Scholar
• Vasilopoulos Y, Manolika M, Zafiriou E, et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther. 2012;16:29–34.
   PubMed Web of Science ®Google Scholar
• Tejasvi T, Stuart PE, Chandran V, et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol. 2012;132:593–600.
   PubMed Web of Science ®Google Scholar
• Prieto-Perez R, Solano-Lopez G, Cabaleiro T, et al. The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis. Pharmacogenomics. 2015;16:1723–1731.
   PubMed Web of Science ®Google Scholar
• Cabaleiro T, Prieto-Perez R, Navarro R, et al. Paradoxical psoriasiform reactions to anti-TNFalpha drugs are associated with genetic polymorphisms in patients with psoriasis. Pharmacogenomics J. 2015;1–5. doi:10.1038/tpj.2015.53. Epub ahead of print.
   Web of Science ®Google Scholar
• Julia M, Guilabert A, Lozano F, et al. The role of Fcgamma receptor polymorphisms in the response to anti-tumor necrosis factor therapy in psoriasis A pharmacogenetic study. JAMA Dermatol. 2013;149:1033–1039.
   PubMed Web of Science ®Google Scholar
• Julia A, Ferrandiz C, Dauden E, et al. Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. Pharmacogenomics J. 2015;15:322–325.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Boca AN, Botti E, et al. IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis. Dermatology. 2015;232:230–236.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169:458–463.
   PubMed Web of Science ®Google Scholar
• Martinez C, Blanco G, Ladero JM, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004;141:205–208.
   PubMed Web of Science ®Google Scholar
• Chandran V, Siannis F, Rahman P, et al. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol. 2010;37:1508–1512.
   PubMed Web of Science ®Google Scholar
• Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics. 2012;13:31–41.
   PubMed Web of Science ®Google Scholar
• Tong Q, Zhao L, Qian XD, et al. Association of TNF-alpha polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. Pharmacogenomics. 2013;14:1691–1700.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gulli R, Spano F, et al. TNF-alpha gene polymorphisms: association with disease susceptibility and response to anti-TNF-alpha treatment in psoriatic arthritis. J Invest Dermatol. 2014;134:2503–2509.
   PubMed Web of Science ®Google Scholar
• Ramirez J, Fernandez-Sueiro JL, Lopez-Mejias R, et al. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-alpha blockers in psoriatic arthritis: a longitudinal study with 6 months of followup. J Rheumatol. 2012;39:1035–1041.
   PubMed Web of Science ®Google Scholar
• Julia A, Rodriguez J, Fernandez-Sueiro JL, et al. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. Pharmacogenomics. 2014;15:1763–1769.
   PubMed Web of Science ®Google Scholar
• Morales-Lara MJ, Canete JD, Torres-Moreno D, et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine. 2012;79:591–596.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
   PubMed Web of Science ®Google Scholar
• Jani M, Barton A, Ho P. Pharmacogenetics of treatment response in psoriatic arthritis. Curr Rheumatol Rep. 2015;17:44.
   PubMed Web of Science ®Google Scholar
• Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57:163–172.
   PubMed Web of Science ®Google Scholar
• Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 2006;54:1366–1377.
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481–508.
   PubMed Web of Science ®Google Scholar
• O’Rielly DD, Rahman P. Pharmacogenetics of psoriasis. Pharmacogenomics. 2011;12:87–101.
   PubMed Web of Science ®Google Scholar
• Das KM, Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet. 1976;1:406–425.
   PubMed Web of Science ®Google Scholar
• Wiese MD, Alotaibi N, O’Doherty C, et al. Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. Pharmacogenomics J. 2014;14:350–355.
   PubMed Web of Science ®Google Scholar
• Davila L, Ranganathan P. Corrigendum: pharmacogenetics: implications for therapy in rheumatic diseases. Nat Rev Rheumatol. 2015;11:258.
   PubMed Web of Science ®Google Scholar
• Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum. 2005;52:710–721.
   PubMed Web of Science ®Google Scholar
• Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;141:3956–3964.
   PubMed Web of Science ®Google Scholar
• Mizutani H, Ohmoto Y, Mizutani T, et al. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci. 1997;14:145–153.
   PubMed Web of Science ®Google Scholar
• Verstrepen L, Carpentier I, Verhelst K, et al. ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling. Biochem Pharmacol. 2009;78:105–114.
   PubMed Web of Science ®Google Scholar
• Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183–3194.
   PubMed Web of Science ®Google Scholar
• Chen X, Tan Z, Yue Q, et al. The expression of interleukin-23 (p19/p40) and interleukin-12 (p35/p40) in psoriasis skin. J Huazhong Univ Sci Technolog Med Sci. 2006;26:750–752.
   PubMedGoogle Scholar
• Chien AL, Elder JT, Ellis CN. Ustekinumab: a new option in psoriasis therapy. Drugs. 2009;69:1141–1152.
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580–592.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Wang TS, Chan CC, et al. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol. 2014;171:1181–1188.
   PubMed Web of Science ®Google Scholar
• Goldminz AM, Suarez-Farinas M, Wang AC, et al. CCL20 and IL22 messenger RNA expression after adalimumab vs methotrexate treatment of psoriasis: a randomized clinical trial. JAMA Dermatol. 2015;151:837–846.
   PubMed Web of Science ®Google Scholar
• Balato A, Schiattarella M, Di Caprio R, et al. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol. 2014;28:1016–1024.
   PubMed Web of Science ®Google Scholar
• Wang CQ, Suarez-Farinas M, Nograles KE, et al. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol. 2014;134:2990–2993.
   PubMed Web of Science ®Google Scholar
• Markham T, Mullan R, Golden-Mason L, et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol. 2006;54:1003–1012.
   PubMed Web of Science ®Google Scholar
• Lembo S, Balato N, Caiazzo G, et al. The effects of etanercept on replication, proliferation, survival, and apoptosis markers in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2016. doi:10.1111/jdv.13583. Epub ahead of print.
   PubMedGoogle Scholar
• Krueger JG, Fretzin S, Suarez-Farinas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130:145–54 e9.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52ra72.
   PubMed Web of Science ®Google Scholar
• Baerveldt EM, Onderdijk AJ, Kurek D, et al. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response. Br J Dermatol. 2013;168:990–998.
   PubMed Web of Science ®Google Scholar
• Balato A, Mattii M, Caiazzo G, et al. IL-36gamma is involved in psoriasis and allergic contact dermatitis. J Invest Dermatol. 2016. doi:10.1016/j.jid.2016.03.020. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Lovendorf MB, Zibert JR, Gyldenlove M, et al. MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. J Dermatol Sci. 2014;75:133–139.
   PubMed Web of Science ®Google Scholar
• Pivarcsi A, Meisgen F, Xu N, et al. Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor-alpha therapy. Br J Dermatol. 2013;169:563–570.
   PubMed Web of Science ®Google Scholar
• Chan ES, Fernandez P, Cronstein BN. Methotrexate in rheumatoid arthritis. Expert Rev Clin Immunol. 2007;3:27–33.
   PubMedGoogle Scholar
• Cuchacovich R, Perez-Alamino R, Zea AH, et al. Distinct genetic profile in peripheral blood mononuclear cells of psoriatic arthritis patients treated with methotrexate and TNF-inhibitors. Clin Rheumatol. 2014;33:1815–1821.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fcfusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–259.
   PubMed Web of Science ®Google Scholar
• Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, et al. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol. 2011;131:391–400.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005;175:2721–2729.
   PubMed Web of Science ®Google Scholar
• Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009;124:1022-10 e1-395.
   PubMed Web of Science ®Google Scholar
• Skarmoutsou E, Trovato C, Granata M, et al. Biological therapy induces expression changes in Notch pathway in psoriasis. Arch Dermatol Res. 2015;307:863–873.
   PubMed Web of Science ®Google Scholar
• Vageli DP, Exarchou A, Zafiriou E, et al. Effect of TNF-alpha inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and toll-like receptors-2 and -9 in psoriatic plaques. Exp Ther Med. 2015;10:1573–1577.
   PubMed Web of Science ®Google Scholar
• Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443–1453.
   PubMed Web of Science ®Google Scholar
• Rosenberg A, Fan H, Chiu YG, et al. Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy. PLoS One. 2014;9:e110657.
   Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–3289.
   PubMed Web of Science ®Google Scholar
• Burness CB, McKeage K. Adalimumab: a review in chronic plaque psoriasis. Drugs. 2015;75:2119–2130.
   PubMed Web of Science ®Google Scholar
• Alunno A, Carubbi F, Cafaro G, et al. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. Expert Opin Biol Ther. 2015;15:1727–1737.
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Krueger G. A role for epigenetics in psoriasis: methylated cytosine-guanine sites differentiate lesional from nonlesional skin and from normal skin. J Invest Dermatol. 2012;132:506–508.
   PubMed Web of Science ®Google Scholar
• Gedebjerg A, Johansen C, Kragballe K, et al. IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. Acta Derm Venereol. 2013;93:150–155.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–1146.
   PubMed Web of Science ®Google Scholar
• Boyd T, Kavanaugh A. Novel approaches to biological therapy for psoriatic arthritis. Expert Opin Biol Ther. 2016;16:173–186.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–1199.
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306:864–871.
   PubMed Web of Science ®Google Scholar
• Jorgensen AL, Williamson PR. Methodological quality of pharmacogenetic studies: issues of concern. Stat Med. 2008;27:6547–6569.
   PubMed Web of Science ®Google Scholar
• O’Rielly DD, Rahman P. Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev Rheumatol. 2011;7:718–732.
   PubMed Web of Science ®Google Scholar
• Bender R, Lange S. Adjusting for multiple testing – when and how? J Clin Epidemiol. 2001;54:343–349.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Zhang JP, Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry. 2012;17:760–769.
   PubMed Web of Science ®Google Scholar
• Bluett J, Morgan C, Thurston L, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford). 2015;54:494–499.
   PubMed Web of Science ®Google Scholar
• Galo JS, Mehat P, Rai SK, et al. What are the effects of medication adherence interventions in rheumatic diseases: a systematic review. Ann Rheum Dis. 2015;75(4):667–673.
   PubMed Web of Science ®Google Scholar
• Vogelzang EH, Kneepkens EL, Nurmohamed MT, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis. 2014;73:2178–2182.
   PubMed Web of Science ®Google Scholar